Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3
Relmada Therapeutics will raise about $160 million in a private placement, priced at $4.75 a share, after reporting 12-month data showing a 76% complete response rate for NDV-01 in non-muscle invasive bladder cancer. The financing, expected to close by March 11, follows FDA feedback backing late-stage studies. NDV-01 showed no cases of disease progression or severe side effects among 25 patients at 12 months.